title: The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia.
abstract: OBJECTIVE
  The soluble urokinase plasminogen activator receptor (suPAR) is a soluble form of the urokinase plasminogen activator receptor expressed in various immune and cancer cells. The levels of suPAR have been demonstrated to correlate with prognosis in various cancers. This study was intended to investigate serum suPAR levels and their effect on prognosis in patients with acute myeloid leukemia (AML).
  
  
  METHODS
  Thirty newly diagnosed patients with AML and 29 healthy individuals were enrolled. Serum suPAR levels were analyzed by enzyme-linked immunosorbent assay.
  
  
  RESULTS
  Serum suPAR levels were significantly higher in patients with AML than in healthy individuals (9±5.9 ng/mL and 2.4±1.4 ng/mL, respectively; p<0.001). Positive correlation was determined between suPAR levels and white blood cell counts (p<0.01). Serum suPAR levels were lower in patients who achieved complete response than in patients not achieving complete response (5.5±2.2 ng/mL and 12±6.6 ng/mL, respectively; p<0.001). The median overall survival was longer in patients with serum suPAR levels below 6.71 ng/mL than in those with serum suPAR levels above 6.71 ng/mL (12.6±13.2 months and 1.71±0.6 months, respectively; p=0.02). Multivariate Cox regression analysis showed that suPAR had independent prognostic value (95% confidence interval: 1.029-6.259; p<0.05) in AML.
  
  
  CONCLUSIONS
  Serum suPAR levels can be used as a prognostic marker in AML.
authors.affiliation: Kanuni Training and Research Hospital, Clinic of Hematology, Trabzon, Turkey, Phone : +90 462 341 56 56 E-mail : drnusta@hotmail.com.
authors.forename: Nergiz
authors.initials: N
authors.lastname: Erkut
authors.forename: Ahmet
authors.initials: A
authors.lastname: Menteşe
authors.forename: Hasan Mücahit
authors.initials: HM
authors.lastname: Özbaş
authors.forename: Nilay
authors.initials: N
authors.lastname: Ermantaş
authors.forename: Ayşegül
authors.initials: A
authors.lastname: Sümer
authors.forename: Asım
authors.initials: A
authors.lastname: Örem
authors.forename: Mehmet
authors.initials: M
authors.lastname: Sönmez
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012372:ROC Curve; D055293:Receptors, Urokinase Plasminogen Activator / Q000097:blood*; D055815:Young Adult
chemical_list: D015415:Biomarkers; D055293:Receptors, Urokinase Plasminogen Activator